Skip to content

PSX Pharmaceuticals

GLAXO GlaxoSmithKline Pakistan Limited

Latest results: FY2025 · Dec 2025 Q2 FY2026 · Apr – Jun 2026

FY2025 revenue Rs 65.9 bn (+7.7%), profit Rs 10.0 bn (+53.4%). Dividend paid 2 years in a row.

Last close · 13 Nov 2026

Rs 336.36 ▼ 1.93 (-0.57%)

▼ 14.6% 1 year

15 Oct 22 Oct 28 Oct 3 Nov 11 Nov Jun Jul Aug Sep Oct Dec Feb May Jul Oct 2022 2023 2024 2025 2026
293.0952-week range459.27
Market cap
Rs 107.1 bn
P/E
10.3×
TTM to Jun 2026
Sector 12.6× · lower
P/B
3.11×
Quarter to Jun 2026
Sector 3.11×
Dividend yield
5.1%
FY2025
Payers 4.7% · higher
ROE
32.4%
FY2025
Sector 21.7% · higher
EPS
Rs 32.69
TTM to Jun 2026
Book value / share
Rs 108.12
Quarter to Jun 2026

Fundamentals

GLAXO at a glance

Revenue · FY2025

Rs 65.9 bn

▲ 7.7% year on year

Profit attributable to shareholders · FY2025

Rs 10.0 bn

▲ 53.4% year on year

EPS – basic (Rs) · FY2025

Rs 31.48

▲ 53.4% year on year

Dividend per share (Rs) · FY2025

Rs 17.00

▲ 70.0% year on year

Net margin · FY2025

15.2%

+4.5 pts year on year

Debt to equity · FY2025

1.1%

+0.5 pts year on year

Price performance

GLAXO returns

Close Rs 336.36
13 Nov 2026

Period Return Rs
MTD +5.3% −1.6 pts vs KSE +16.97
3M −2.4% −1.2 pts vs KSE −8.34
6M −3.5% −9.8 pts vs KSE −12.28
YTD −13.7% −15.9 pts vs KSE −53.42
1Y −14.6% −25.4 pts vs KSE −57.65
Long term
3Y +306.9% +59.7% a year +92.3 pts vs KSE +253.70
5Y +131.5% +18.3% a year −157.3 pts vs KSE +191.07

Price return from the last close before each period; the fiscal year ends 31 December, so year to date is also fiscal year to date. Dividends are not included.

GlaxoSmithKline Pakistan Limited in brief

GlaxoSmithKline Pakistan Limited (GLAXO) reported revenue of Rs 65.9 bn for FY2025 (Jan – Dec 2025), up 7.7% from FY2024.

Profit attributable to shareholders was Rs 10.0 bn (EPS Rs 31.48), up 53.4%, a net margin of 15.2%.

It declared a dividend of Rs 17.00 per share for FY2025.

The balance sheet showed net cash of Rs 8.2 bn.

Return on equity was 32.4%.

Over the last five years revenue grew at a compound 13.4% a year.

At Rs 336.36 (close on 13 Nov 2026) the shares trade at 10.3× earnings (TTM to Jun 2026) and 3.11× book value, with a dividend yield of 5.1%.

Scorecard vs Pharmaceuticals

14 companies
Growth
Average
16.3%
Profitability
Strong
15.2%
Financial health
Strong
1.1%
Valuation
Strong
10.3×
Dividends
Above average
5.1%

Ratings place the company in its sector: growth (3-year revenue growth), profitability (net margin; return on equity for banks, insurers and finance companies), financial health (debt to equity, industrial companies), valuation (P/E at today's price) and dividends (yield at today's price). Five dots = top fifth. Rated within the sector when at least four companies report the figure, otherwise against all PSX companies of the same type (marked vs PSX). Information, not investment advice.

Corporate

GLAXO announcements & payouts

All GLAXO announcements →
29 Oct 2026 · 16:04
Result · Nine months to 30 Sep 2026
Profit after tax
Rs 7,191.1 mn
EPS
Rs 22.58 +15.4%
EPS a year earlier
Rs 19.57
25 Aug 2026 · 15:39
Result · Half year to 30 Jun 2026 Cash 70% · Rs 7.00 · Interim 1
Profit after tax
Rs 4,580.6 mn
EPS
Rs 14.38 +9.2%
EPS a year earlier
Rs 13.17

Book closure 3 Sep – 4 Sep 2026 · Buy by Mon 31 Aug (est.) for the payout

28 Apr 2026 · 12:06
Result · First quarter to 31 Mar 2026
Profit after tax
Rs 2,610.7 mn
EPS
Rs 8.20 +22.8%
EPS a year earlier
Rs 6.68
26 Mar 2026 · 15:54
Result · Full year to 31 Dec 2025 Cash 120% · Rs 12.00 · Final AGM 30 Apr
Profit after tax
Rs 10,025.3 mn
EPS
Rs 31.48 +53.4%
EPS a year earlier
Rs 20.52

Book closure 23 Apr – 30 Apr 2026 · Buy by Mon 20 Apr (est.) for the payout

Financial highlights

GLAXO financial results

GLAXO annual financial highlights (Rs bn)
Rs bn FY2025 Jan – Dec 2025 FY2024 Jan – Dec 2024 FY2023 Jan – Dec 2023 FY2022 Jan – Dec 2022 FY2021 Jan – Dec 2021 FY2020 Jan – Dec 2020 FY2019 Jan – Dec 2019 FY2018 Jan – Dec 2018 FY2017 Jan – Dec 2017 FY2016 * Jan – Dec 2016
Revenue 65.9 61.2 49.7 41.8 36.7 35.1 36.6 34.0 32.8 27.6
Gross profit 24.4 15.4 3.4 7.3 9.9 7.7 7.7 8.4 8.9 7.5
Operating profit 16.4 10.2 1.6 4.2 7.4 4.9 4.7 4.7 5.0 4.2
Profit after tax 10.0 6.5 0.5 2.5 5.4 3.4 3.0 3.2 3.0 2.6
Profit attributable to shareholders 10.0 6.5 0.5 2.5 5.4 3.4 3.0 3.3 3.0 2.8
EPS – basic (Rs) Rs 31.48 20.52 1.68 7.73 16.81 10.60 9.55 10.23 9.36 8.67
Dividend per share (Rs) Rs 17.00 10.00 0.00 0.00 7.00 6.50 6.00 7.00 7.00 6.00
Total assets 50.7 45.1 38.1 35.5 30.5 26.1 23.2 22.2 21.9 21.2
Total equity 33.7 28.3 21.7 21.1 21.0 17.5 16.1 15.4 13.5 13.5
Total debt 0.4 0.2 0.2 0.1 0.1 0.0 0.1 — — —
Net cash from operating activities 9.2 5.6 1.9 (2.3) 5.4 6.5 2.7 3.1 2.3 4.4
Capital expenditure (2.6) (2.8) (1.6) (1.5) (1.3) (1.3) (1.3) (0.9) (1.6) (1.9)
Free cash flow (operating cash flow − capex) 6.6 2.8 0.2 (3.9) 4.1 5.2 1.4 2.3 0.7 2.6
GLAXO quarterly financial highlights (Rs bn)
Rs bn TTM to Jun 2026 Q2 FY2026 Apr – Jun 2026 Q1 FY2026 Jan – Mar 2026 Q4 FY2025 Oct – Dec 2025 Q3 FY2025 Jul – Sep 2025 Q2 FY2025 Apr – Jun 2025 Q1 FY2025 Jan – Mar 2025 Q4 FY2024 Oct – Dec 2024 Q3 FY2024 Jul – Sep 2024
Revenue 67.1 14.5 17.0 21.4 14.2 14.7 15.6 17.6 14.7
Gross profit 25.6 5.5 6.4 8.5 5.2 5.4 5.3 5.8 4.0
Operating profit 16.8 3.2 4.3 6.1 3.2 3.4 3.6 4.7 2.7
Profit after tax 10.4 2.0 2.6 3.8 2.0 2.1 2.1 3.0 1.9
Profit attributable to shareholders 10.4 2.0 2.6 3.8 2.0 2.1 2.1 3.0 1.9
EPS – basic (Rs) Rs 32.69 6.19 8.20 11.91 6.40 6.50 6.68 9.27 6.05
Dividend per share (Rs) Rs 19.00 7.00 0.00 12.00 0.00 5.00 0.00 10.00 0.00
Total assets 52.6 52.6 54.0 50.7 51.0 48.1 48.8 45.1 47.3
Total equity 34.4 34.4 36.3 33.7 29.7 29.3 30.4 28.3 25.3
Total debt 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.2 0.2
Net cash from operating activities 9.5 2.6 1.7 2.6 2.6 3.9 0.1 0.4 2.7
Capital expenditure (2.4) (0.4) (0.3) (1.0) (0.6) (0.5) (0.5) (1.2) (0.5)
Free cash flow (operating cash flow − capex) 7.1 2.2 1.3 1.6 2.0 3.4 (0.4) (0.8) 2.2

Figures in Pakistani rupees as reported by the company; costs and cash outflows in brackets. Free cash flow and book value per share are calculated by Smart Money; TTM = the latest four quarters. Updated 17 Oct 2026.

GLAXO charts

Revenue and profit Revenue Profit attributable
Revenue and profit Rs 66 bn Revenue FY16: Rs 27.6 bn Profit attributable FY16: Rs 2.8 bn FY16 Revenue FY17: Rs 32.8 bn Profit attributable FY17: Rs 3.0 bn FY17 Revenue FY18: Rs 34.0 bn Profit attributable FY18: Rs 3.3 bn FY18 Revenue FY19: Rs 36.6 bn Profit attributable FY19: Rs 3.0 bn FY19 Revenue FY20: Rs 35.1 bn Profit attributable FY20: Rs 3.4 bn FY20 Revenue FY21: Rs 36.7 bn Profit attributable FY21: Rs 5.4 bn FY21 Revenue FY22: Rs 41.8 bn Profit attributable FY22: Rs 2.5 bn FY22 Revenue FY23: Rs 49.7 bn Profit attributable FY23: Rs 534.0 mn FY23 Revenue FY24: Rs 61.2 bn Profit attributable FY24: Rs 6.5 bn FY24 Revenue FY25: Rs 65.9 bn Profit attributable FY25: Rs 10.0 bn FY25
Margins Gross margin Operating margin Net margin
Margins 40% 20% 0% Gross margin FY16: 27.1% Gross margin FY17: 27.1% Gross margin FY18: 24.8% Gross margin FY19: 21.0% Gross margin FY20: 22.0% Gross margin FY21: 26.9% Gross margin FY22: 17.5% Gross margin FY23: 6.9% Gross margin FY24: 25.1% Gross margin FY25: 37.0% Operating margin FY16: 15.2% Operating margin FY17: 15.4% Operating margin FY18: 13.9% Operating margin FY19: 12.9% Operating margin FY20: 14.0% Operating margin FY21: 20.1% Operating margin FY22: 9.9% Operating margin FY23: 3.3% Operating margin FY24: 16.7% Operating margin FY25: 24.9% Net margin FY16: 9.6% Net margin FY17: 9.2% Net margin FY18: 9.5% Net margin FY19: 8.3% Net margin FY20: 9.6% Net margin FY21: 14.6% Net margin FY22: 5.9% Net margin FY23: 1.1% Net margin FY24: 10.7% Net margin FY25: 15.2% FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25
Cash flow Operating cash flow Capex Free cash flow
Cash flow Rs 9 bn -Rs 4 bn Operating cash flow FY16: Rs 4.4 bn Capex FY16: -Rs 1.9 bn Free cash flow FY16: Rs 2.6 bn FY16 Operating cash flow FY17: Rs 2.3 bn Capex FY17: -Rs 1.6 bn Free cash flow FY17: Rs 678.8 mn FY17 Operating cash flow FY18: Rs 3.1 bn Capex FY18: -Rs 854.5 mn Free cash flow FY18: Rs 2.3 bn FY18 Operating cash flow FY19: Rs 2.7 bn Capex FY19: -Rs 1.3 bn Free cash flow FY19: Rs 1.4 bn FY19 Operating cash flow FY20: Rs 6.5 bn Capex FY20: -Rs 1.3 bn Free cash flow FY20: Rs 5.2 bn FY20 Operating cash flow FY21: Rs 5.4 bn Capex FY21: -Rs 1.3 bn Free cash flow FY21: Rs 4.1 bn FY21 Operating cash flow FY22: -Rs 2.3 bn Capex FY22: -Rs 1.5 bn Free cash flow FY22: -Rs 3.9 bn FY22 Operating cash flow FY23: Rs 1.9 bn Capex FY23: -Rs 1.6 bn Free cash flow FY23: Rs 225.2 mn FY23 Operating cash flow FY24: Rs 5.6 bn Capex FY24: -Rs 2.8 bn Free cash flow FY24: Rs 2.8 bn FY24 Operating cash flow FY25: Rs 9.2 bn Capex FY25: -Rs 2.6 bn Free cash flow FY25: Rs 6.6 bn FY25

Valuation

GLAXO valuation at today's price

Price to earnings (P/E)
10.3×
EPS Rs 32.69 (TTM to Jun 2026)
Price to book (P/B)
3.11×
Book value Rs 108.12 (Quarter to Jun 2026)
Dividend yield
5.1%
DPS Rs 17.00 (FY2025)
Earnings yield
9.7%
EPS ÷ price

At the closing price of Rs 336.36 on 13 Nov 2026. P/E and P/B are not shown when earnings or book value are negative.

Sector peers

GLAXO vs Pharmaceuticals companies

Largest companies in the sector at today's prices
Company Market cap P/E P/B Yield ROE 3-yr growth
GLAXO Rs 107.1 bn 10.3× 3.11× 5.1% 32.4% 16.3%
ABOT Rs 97.9 bn 11.4× 3.05× 4.0% 28.8% 15.2%
HALEON Rs 81.6 bn 12.4× 5.02× 4.3% 47.6% 16.2%
HINOON Rs 50.8 bn 12.8× 3.95× 5.2% 32.3% 20.5%
AGP Rs 43.8 bn 11.7× 2.92× 5.1% 25.9% 26.0%
HPL Rs 38.5 bn 10.3× 4.50× 6.0% 38.6% 18.6%
FEROZ Rs 15.8 bn 16.1× 1.19× 1.5% 7.6% 27.9%
CPHL Rs 14.5 bn 18.3× 1.34× 0.0% 7.3% 4.3%
MACTER Rs 12.0 bn 17.7× 2.87× 0.0% 17.4% 20.7%

All Pharmaceuticals companies, medians and leaders →

Compare

Compare GLAXO with

Analyses & signals 0

Win rate — · 0 closed signals · average return —

No analyses published for GLAXO yet.

GLAXO: frequently asked questions

What is GLAXO's EPS?

GlaxoSmithKline Pakistan Limited reported basic earnings per share of Rs 31.48 for FY2025 (Jan – Dec 2025). Over the trailing twelve months (TTM to Jun 2026) EPS was Rs 32.69.

What is GLAXO's P/E ratio?

At the closing price of Rs 336.36 on 13 Nov 2026, GLAXO trades at a P/E of 10.3× based on EPS of Rs 32.69 (TTM to Jun 2026).

Does GLAXO pay dividends?

Yes. GlaxoSmithKline Pakistan Limited declared a dividend of Rs 17.00 per share for FY2025. It has paid a dividend in each of the last 2 years. At Rs 336.36 that is a dividend yield of 5.1%.

What was GLAXO's revenue and profit in FY2025?

GlaxoSmithKline Pakistan Limited reported revenue of Rs 65.9 bn and profit attributable to shareholders of Rs 10.0 bn for FY2025 (Jan – Dec 2025).

What is GLAXO's book value per share?

GlaxoSmithKline Pakistan Limited's book value per share was Rs 105.74 at the end of FY2025. The shares trade at 3.11× book value.

How has GLAXO's share price performed?

GLAXO's share price is down 13.7% year to date (KSE-100: +2.2%), down 14.6% over one year (KSE-100: +10.7%) and up 131.5% over five years (KSE-100: +288.8%), as of 13 Nov 2026. These are price returns; dividends are not included.

Information only, not investment advice.